言語を選択
Glypican 3
Glypican 3 詳細
| 英語名 | Glypican-3 | 市販薬剤の数 | 0 |
| 治験薬の数 | 58 | ターゲットの別称 | MXR7，OCI5，GPC3，Glypican-3，Glypican 3，Glypican Proteoglycan 3，GTR2-2，Secreted Glypican-3，OCI-5，SGBS1，DGSX，SGBS，SDYS，SGB，Intestinal protein OCI-5，Heparan Sulphate Proteoglycan |
| 研究＆開発段階 | Phase 2 Clinical | ||
| 英語名 | Glypican-3 |
| ターゲットの別称 | MXR7，OCI5，GPC3，Glypican-3，Glypican 3，Glypican Proteoglycan 3，GTR2-2，Secreted Glypican-3，OCI-5，SGBS1，DGSX，SGBS，SDYS，SGB，Intestinal protein OCI-5，Heparan Sulphate Proteoglycan |
| 市販薬剤の数 | 0 |
| 治験薬の数 | 58 |
| 研究＆開発段階 | Phase 2 Clinical |
Glypican 3 製品リスト
- 属性
Protein (23)Cell (3)Beads (2)
- 製品ライブラリ
オンライン (28)
- 種
Human (20)Cynomolgus (4)Mouse (3)Rat (1)
- タグ
His Tag (15)Fc Tag (5)His Tag & Avi Tag (1)Llama IgG Fc Tag (2)- (5)
- マーカー
Unconjugated (14)Biotin-labeled (1)FITC Labeled (2)PE Labeled (2)APC Labeled (3)AF488 Labeled (1)- (5)
総数量28
- 1
- 2
- 3
Glypican 3バックグランド
Glypican-3 (GPC3) is also known as Intestinal protein OCI-5, GTR2-2, MXR7, which belongs to the glypican family. Glypican 3 / GPC-3 is highly expressed in lung, liver and kidney. Glypican-3 inhibits the dipeptidyl peptidase activity of DPP4. Glypican-3 may be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs, and also may play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function.
Glypican 3分子の別称
GPC3,OCI5,Glypican-3,GTR2-2,MXR7,DGSX,SDYS ,SGB,SGBS,SGBS1
治験薬に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| GPC-3298306 | GPC-3298306 | Phase 2 Clinical | National Cancer Center Of Japan | Carcinoma, Hepatocellular; Ovarian Neoplasms | 詳細 |
| BOS-342 | PRS-342; BOS-342; PRS-342/BOS-342 | Phase 2 Clinical | Pieris Pharmaceuticals | Carcinoma, Hepatocellular; Solid tumours | 詳細 |
| BOXR-1030 | BOXR-1030 | Phase 2 Clinical | Unum Therapeutics Inc | Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Squamous Cell; Liposarcoma, Myxoid; Liver Neoplasms; Lung Neoplasms | 詳細 |
| GPC3 targeting CAR-T cell therapy (Essen Biotech) | Phase 2 Clinical | Essen Biotech | Carcinoma, Ovarian Epithelial; Ovarian Neoplasms | 詳細 | |
| AZD-9793 | AZD9793; AZD-9793 | Phase 2 Clinical | Astrazeneca Plc | Carcinoma, Hepatocellular; Neoplasm Metastasis; Solid tumours | 詳細 |
| CAR-T Cell Therapy Targeting GPC3(Pla General Hospital) | Phase 2 Clinical | Pla General Hospital | Carcinoma, Hepatocellular | 詳細 | |
| MRG-006 | MRG-006A; MRG-006 | Phase 2 Clinical | Shanghai Miracogen Inc | Carcinoma, Hepatocellular; Liver Neoplasms; Neoplasms; Solid tumours | 詳細 |
| C-CAR031 | C-CAR031; AZD-7003; TC-CAR-031; TC-CAR031; C-CAR-031 | Phase 2 Clinical | Astrazeneca Plc | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | 詳細 |
| NY-303 | NY-303 | Phase 2 Clinical | NAYA Biosciences Inc | Carcinoma, Hepatocellular; Solid tumours | 詳細 |
| AZD-5851 | AZD-5851; AZD5851 | Phase 2 Clinical | Astrazeneca Plc | Carcinoma, Hepatocellular | 詳細 |
| NWRD-06 | NWRD-06; NWRD06 | Phase 2 Clinical | Newish Technology (Beijing) Co Ltd | Carcinoma, Hepatocellular | 詳細 |
| GKL-006 | GKL-006; GKL006 | Phase 2 Clinical | Beijing Gene Key Life Technology Co Ltd | Carcinoma, Hepatocellular; Liver Neoplasms; Pancreatic Neoplasms; Psoriasis | 詳細 |
| CMD-011 | CMD-011 | Phase 2 Clinical | Zhejiang Shimai Pharmaceutical Co Ltd | Carcinoma, Hepatocellular; Liver Neoplasms | 詳細 |
| CAR-GPC3 T-cell (Drum Tower Hospital) | Phase 2 Clinical | Nanjing Drum Tower Hospital | Carcinoma, Hepatocellular | 詳細 | |
| GPC3 CAR-T therapy (Hrain Biotechnology) | Phase 2 Clinical | Hrain Biotechnology Co Ltd | Carcinoma, Hepatocellular | 詳細 | |
| CM-350 | CM-350 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Solid tumours | 詳細 |
| GPC3-CAR-T cell therapy(Origincell Medical Technology) | Ori-CAR-001; Ori-C101（OriCell） | Phase 2 Clinical | OriCell Therapeutics Co Ltd | Carcinoma, Hepatocellular | 詳細 |
| ECT-204 | ECT-204; JWATM-204; ECT204 | Phase 2 Clinical | Eureka Therapeutics Inc, Jw Therapeutics (Shanghai) Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Liver Neoplasms | 詳細 |
| Codrituzumab | GC-33; RO-5137382; RG-7686; ERY-974; PPMX-T001 | Phase 1 Clinical | Perseus Proteomics Inc | Carcinoma, Hepatocellular; Solid tumours | 詳細 |
| GPC3-T2 CAR-T cell therapy (The Second Affiliated Hospital of Guangzhou Medical University) | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Carcinoma, Hepatocellular; Carcinoma, Squamous Cell | 詳細 | |
| GLYCAR T cell therapy (Baylor College of Medicine) | GLYCAR | Phase 1 Clinical | Baylor College Of Medicine | Carcinoma, Hepatocellular; Endodermal Sinus Tumor; Hepatoblastoma; Liposarcoma; Liver Neoplasms; Rhabdoid Tumor; Rhabdomyosarcoma; Wilms Tumor | 詳細 |
| Anti-GPC3 CAR T-cell therapy (Carbiogene Therapeutics) | CBG166; CBG-166 | Phase 1 Clinical | Carbiogene Therapeutics Co Ltd, Nanjing University | Carcinoma, Hepatocellular | 詳細 |
| GPC3-CAR-T cell therapy | CSG-GPC-3; CAR-GPC3 T-cell; GPC3-CAR/CSG-GPC3; anti-GPC-3 CAR T; KJgpc3-001; CT-011 | Phase 1 Clinical | Carsgen Biomedicine (Shanghai) Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Solid tumours | 詳細 |
| Anti-GPC3 chimeric antigen receptor T cell therapy (Hunan Zhaotai Yongren Biotech/Guangdong Zhaotai Invivo Biomedicine) | Phase 1 Clinical | Guangdong Zhaotai Invivo Biomedicine Co Ltd, Hunan Zhaotai Yongren Biotech Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | 詳細 | |
| anti-GPC3 CAR T-cell therapy (National Institutes of Health Clinical Center) | Phase 1 Clinical | National Institutes Of Health Clinical Center (Cc) | Carcinoma, Hepatocellular | 詳細 | |
| anti-GPC3 CAR T-cell therapy (Nanjing Drum Tower Hospital) | Phase 1 Clinical | Nanjing Drum Tower Hospital | Carcinoma, Hepatocellular | 詳細 | |
| GPC3-T2-CAR-T | GPC3-T2-CAR-T | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Carcinoma, Hepatocellular | 詳細 |
| EU-307 | EU307 | Phase 1 Clinical | Eutilex | Carcinoma, Hepatocellular; Liver Neoplasms | 詳細 |
| Ori-CAR-002 | Ori-CAR-002; GPC3-CAR-Ori2 | Phase 1 Clinical | OriCell Therapeutics Co Ltd | Multiple Myeloma | 詳細 |
| SENTI-301 | SENTI-301; SENTI-301A; SN301A | Phase 1 Clinical | Senti Biosciences Inc | Carcinoma, Hepatocellular; Liver Neoplasms | 詳細 |
| Super CAR-T cell therapy (FineImmune Biotechnology) | Phase 1 Clinical | Guangzhou Fineimmune Biotechnology | Carcinoma, Hepatocellular | 詳細 | |
| TC-G203 | TC-G203; TCG203 | Phase 1 Clinical | Beijing GoBroad Hospital | Carcinoma, Hepatocellular; Solid tumours | 詳細 |
| I-124 Codrituzumab | Phase 1 Clinical | Chugai Pharmaceutical Co Ltd, Hoffmann-La Roche Inc, Memorial Sloan Kettering Cancer Center | Carcinoma, Hepatocellular | 詳細 | |
| 225Ac-RYZ-811 | 225Ac-RYZ-811 | Phase 1 Clinical | PeptiDream Inc | Carcinoma, Hepatocellular | 詳細 |
| OriC-902 | OriC-902; OriC902 | Phase 1 Clinical | OriCell Therapeutics Co Ltd | Carcinoma, Hepatocellular | 詳細 |
| BAY-3547926 | BAY3547926; BAY-3547926 | Phase 1 Clinical | Bayer AG | Carcinoma, Hepatocellular | 詳細 |
| MT-303(Myeloid) | MT-303(Myeloid) | Phase 1 Clinical | Myeloid Therapeutics Inc | Carcinoma, Hepatocellular | 詳細 |
| 68Ga-aGPC3-scFv/Fab | 68Ga-aGPC3-scFv/Fab | Phase 1 Clinical | Wuhan Union Hospital | Liver Neoplasms | 詳細 |
| BGB-B2033 | BGB-B-2033; BGB-B2033 | Phase 1 Clinical | Beigene Guangzhou Biologics Manufacturing Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| BC-2027 | BC2027; BC-2027 | Phase 1 Clinical | Wuxi BioCity | Liver Neoplasms; Solid tumours | 詳細 |
| JMT-106 | JMT106; JMT-106 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd | Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Solid tumours | 詳細 |
| AST-201 (Aptamer Sciences) | AST-201(Aptamer Sciences) | Phase 1 Clinical | Aptamer Sciences Inc | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Liver Neoplasms; Neoplasms; Solid tumours | 詳細 |
| GPC3/Mesothelin-CAR-γδT Cells therapy(Second Affiliated Hospital Of Guangzhou Medical University) | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Liver Neoplasms; Lung Neoplasms; Mesothelioma; Pancreatic Neoplasms; Solid tumours | 詳細 | |
| ZW-251 | ZW-251 | Phase 1 Clinical | Zymeworks Inc | Carcinoma, Hepatocellular | 詳細 |
| 68Ga-RYZ-811 | RYZ811(68Ga); 68Ga-Ga-RYZ-GPC3; 68Ga-GPC3; 68Ga-RYZ-811; RYZ-811 | Phase 1 Clinical | PeptiDream Inc, RayzeBio Inc | Carcinoma, Hepatocellular | 詳細 |
| GPC3-targeted CAR-T (Peking University) | Phase 1 Clinical | Peking University | Carcinoma, Hepatocellular | 詳細 | |
| CAR (hYP7)-T cells (National Cancer Institute) | Phase 1 Clinical | National Cancer Institute | Carcinoma, Hepatocellular | 詳細 | |
| QLS-31903 | QLS31903; QLS-31903 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours | 詳細 |
| SAR-444200 | SAR-444200 | Phase 1 Clinical | Sanofi | Neoplasms; Solid tumours | 詳細 |
| IM-83 CAR-T cell therapy | IM-83; IM83 | Phase 1 Clinical | Imunopharm Technology Co Ltd | Carcinoma, Hepatocellular; Liver Neoplasms; Neoplasms; Osteosarcoma | 詳細 |
| JWATM-214 | JWATM-214; JWATM214 | Phase 1 Clinical | Suzhou Yaomingjunuo Biotechnology Co Ltd | Carcinoma, Hepatocellular; Liver Neoplasms | 詳細 |
| TH-012(Bangentai Biomedical) | TH-012 | Phase 1 Clinical | Shandong Bangentai Biomedical Tech Group Co Ltd | Pancreatic Neoplasms; Stomach Neoplasms | 詳細 |
| B010-A | B010-A | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Carcinoma, Hepatocellular | 詳細 |
| CT-0180 | CT-0180 | Phase 1 Clinical | CARsgen Therapeutics Holdings Ltd | Carcinoma, Hepatocellular | 詳細 |
| HRAIN-011 | HRAIN-011 | Clinical | Hrain Biotechnology Co Ltd | Carcinoma, Hepatocellular | 詳細 |
| [68Ga]Ga-NOTA-G5 | Clinical | Renji Hospital Affiliated To Shanghai Jiaotong University School Of Medicine | Digestive System Neoplasms | 詳細 | |
| [18F]F-RESCA-G5 | Clinical | Renji Hospital Affiliated To Shanghai Jiaotong University School Of Medicine | Digestive System Neoplasms | 詳細 | |
| Anti-GPC3-IRDye800CW | Clinical | Chinese Academy Of Sciences | 詳細 |
レビュー
1***62019-10-11
4評価GPC3 is also currently a popular target for solid tumors. I bought this product to detect the positive rate of CAR-T cells. The result was the same with the one performed using our own purified expressed protein (added hFc tag, which requires fluorescent labeled secondary antibodies). But no need to dye for secondary antibodies, so this one from ACRO was more convenient.
- 詳細
- 製品リスト
- レビュー
- 治験薬に関する情報
共有：
メッセージ
お問い合わせ
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
メールアドレス
order.jp@acrobiosystems.com
アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8